期刊文献+

UbcH10基因沉默对多发性骨髓瘤U-1996细胞增殖和凋亡的作用研究 被引量:1

The effects of UbcH10 gene silencing on proliferation and apoptosis research of multiple myeloma U-1996 cell
下载PDF
导出
摘要 目的采用脂质体法转染siRNA的方法沉默多发性骨髓瘤U-1996细胞中的UbcH10基因,研究基因沉默后U-1996细胞增殖活性及凋亡等生物学特性的变化情况。方法根据UbcH10基因信息,设计针对UbcH10基因编码序列(CDS)区的siRNA序列。通过脂质体法转染相关siRNA序列至多发性骨髓瘤U-1996细胞。在转染siRNA后48h,采用实时定量聚合酶链反应及蛋白免疫印迹法检测U-1996细胞中UbcH10基因的mRNA和其蛋白水平。选取未转染siRNA序列的空白组和转染阴性siRNA序列组作为试验对照,采用CCK-8法检测转染siRNA序列后24、48、72hU-1996细胞的增殖情况,采用流式细胞术检测48h后U-1996细胞的凋亡情况。结果通过脂质体法成功转染构建siRNA序列至U-1996细胞。转染后的U-1996细胞中UbcH10基因的mRNA及蛋白表达情况较转染前均明显下降,差异有统计学意义(P<0.05)。和对照组相比,沉默UbcH10基因后U-1996细胞的增殖活性下降,差异有统计学意义(P<0.05),细胞凋亡率上升,差异也有统计学意义(P<0.05)。结论干扰UbcH10基因表达可显著抑制多发性骨髓瘤细胞的增殖活性并增加细胞凋亡。 Objective To investigate the effects of UbcH10 gene silencing on proliferation and apoptosis of myeloma cell line U-1996.Methods According to the UbcH10 genetic information,the siRNA sequence targeting UbcH10 was designed.It was transfected into U-1996 cells via lipofectamine2000.UbcH10 mRNA and protein were examined 48 hafter transfection FQ-PCR and western blot,respectively.Cells without transfection were served as blank controls and those transfected with negative sequence as negative controls.The cell proliferation was detected by CCK-8assay 24 h,48hand 72 hafter transfection,and the cell apoptosis was detected by flow cytometry 48 hafter transfection.Results The siRNA sequence was transfected into U-1996 cells via lipofectamine successfully.The expression level of UbcH10 mRNA and protein was significantly decreased than before transfection(P〈0.05).Compared with control group,the proliferative activity of U-1996 cells after UbcH10 gene silencing was significantly decreased(P〈0.05),the apoptosis rate was significantly incresased(P〈0.05).Conclusion UbcH10 gene silencing can significantly inhibit the proliferative activity of U-1996 cells and increase the cells apoptosis.
出处 《检验医学与临床》 CAS 2016年第12期1603-1605,共3页 Laboratory Medicine and Clinic
基金 国家自然科学基金面上资助项目(81372529)
关键词 UBCH10 多发性骨髓瘤 SIRNA 细胞增殖 细胞凋亡 UbcH10 multiple myeloma siRNA proliferation apoptosis
  • 相关文献

参考文献12

  • 1Rajkumar SV,Kyle RA. Multiple myeloma:diagnosis and treatment[-J. Mayo Clin Proc, 2005,80(10) : 1371-1382.
  • 2Datta K, Suman S, Kumar S, et al. Colorectat carcinogene- sis,radiation quality, and the ubiquitin-proteasome path- way[J]. J Cancer,2016,7(2) :174-183.
  • 3Xie C, Powell C, Yao M, et al. Ubiquitin-conjugating en- zyme E2C:a potential cancer biomarker[-J. Int J Biochem Cell Biol,2014,47(2) .113-117.
  • 4奚昊,侯健.老年多发性骨髓瘤诊治策略[J].实用老年医学,2013,27(9):712-716. 被引量:2
  • 5Nath S, Banerjee T, Sen D, et al. Spindle assembly check- point protein Cdc2O transcriptionally activates expression of ubiquitin carrier protein UbcH10 [J]. J Biol Chern, 2011,286(18) : 15666-15677.
  • 6赵黎明,孙光远,娄丽蓉,王良哲,方正,修清玉.UbcH10基因沉默对肺癌NCI-H226细胞增殖及细胞周期的影响[J].第二军医大学学报,2012,33(6):608-612. 被引量:2
  • 7Okamoto Y, Ozaki T, Miyazaki K, et al. UbcHlO is the cancer-related E2 ubiquitin-conjugating enzyme[J]. Canc- er Res, 2003,63 (14) : 4167-4173.
  • 8van Ree JH ,Jeganathan KB, Malureanu L. Overexpression of the E2 ubiquitin-conjugating enzyme UbcH10 causes chromosome missegregation and tumor formation [J]. J Cell Biol,2010,188(1) :83-100.
  • 9Jiang L,Bao Y,Luo C,et al. Knockdown of ubiquitin-con- jugating enzyme E2C/UbcH10 expression by RNA inter- ference inhibits glioma cell proliferation and enhances cell apoptosis in vitro[-J. J Cancer Res Clin Oncol, 2010,136 (2) :211-217.
  • 10Zhao LM,Jiang L, Wang LZ, et al. UbcH10 expression provides a useful tool for the prognosis and treatment of non-small cell lung cancer[J]. J Cancer Res Clin Oncol, 2012,138(11) :1951-1961.

二级参考文献12

  • 1沈维干.RNA interference and its current application in mammals[J].Chinese Medical Journal,2004(7):1084-1091. 被引量:20
  • 2Palumbo A,Bringhen S,Ludwig H,et al.Personalized therapy in multiple myeloma according to patient age and vulnerability:a report of the European Myeloma Network (EMN)[].Blood.2011
  • 3Fayers PM,Palumbo A,Hulin C,et al.Thalidomide for previously untreated elderly patients with multiple myeloma:meta-analysis of 1685 individual patient data from 6 randomized clinical trials[].Blood.2011
  • 4Morgan GJ,Davies FE,Gregory WM, et al.Cyclophosphamide, thalidomide, anddexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologoustransplantation[].Blood.2011
  • 5Mateos MV,Oriol A,Martinez-Lopez J,et al.Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial[].Blood.2012
  • 6Siegel R,Ward E,Brawley O,et al.Cancer statistics,2011:the impact of eliminating socioeconomic and racial disparities on premature cancer deaths[].CA A Cancer Journal for Clinicians.2011
  • 7Gaballa MR,Laubach JP,Schlossman RL.Management of myelomaassociated renal dysfunction in the era of novel therapies[].Expert Rev Hematol.2012
  • 8Ludwig H,Adam Z,Tóthov E, et al.Thalidomide maintenance treatment increasesprogression-free but not overall survival in elderly patients with myeloma[].Haematologica.2010
  • 9Ferretti E,Lazzarino M.Zoledron ic acid exerts its antitumoreffect in mu ltiple myeloma interfering w ith the bone marrow m i-croenvironm ent[].Hematology.2005
  • 10Palumbo A,Gay F,Falco P,et al.Bortezomib as induction before autologous transplantation,followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients[].Journal of Clinical Oncology.2010

共引文献2

同被引文献7

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部